Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Enterprise Value (2022 - 2025)

Oramed Pharmaceuticals' Enterprise Value history spans 4 years, with the latest figure at -$56.9 million for Q4 2025.

  • For Q4 2025, Enterprise Value changed N/A year-over-year to -$56.9 million; the TTM value through Dec 2025 reached -$56.9 million, changed N/A, while the annual FY2025 figure was -$56.9 million, N/A changed from the prior year.
  • Enterprise Value reached -$56.9 million in Q4 2025 per ORMP's latest filing, down from -$5.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$5.9 million in Q3 2025 to a low of -$155.0 million in Q3 2022.
  • Average Enterprise Value over 4 years is -$86.3 million, with a median of -$97.2 million recorded in 2024.
  • Peak YoY movement for Enterprise Value: soared 93.94% in 2023, then plummeted 1857.84% in 2024.
  • A 4-year view of Enterprise Value shows it stood at -$152.6 million in 2022, then surged by 31.04% to -$105.3 million in 2023, then increased by 18.52% to -$85.8 million in 2024, then soared by 33.62% to -$56.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Enterprise Value are -$56.9 million (Q4 2025), -$5.9 million (Q3 2025), and -$58.9 million (Q2 2025).